Prevention of influenza by targeting host receptors using engineered proteins

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 17, 2014, Pages 6401-6406

  Connaris, Helen ^a   Govorkova, Elena A ^b   Ligertwood, Yvonne ^c   Dutia, Bernadette M ^c   Yang, Lei ^a   Tauber, Sandra ^a   Taylor, Margaret A ^a   Alias, Nadiawati ^a   Hagan, Robert ^a   Nash, Anthony A ^c   Webster, Robert G ^b   Taylor, Garry L ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Drug discovery; Recombinant protein therapy

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; SP 2CBMTD; SP2CBMTD; UNCLASSIFIED DRUG; VC 2CBMTD; VC 4CBM; VC2CBMTD; VC4CBM;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOLOGICAL THERAPY; CHRONOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS; LD 50; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN TARGETING; REPEATED DRUG DOSE; SINGLE DRUG DOSE; VIRUS REPLICATION;

DRUG DISCOVERY; RECOMBINANT PROTEIN THERAPY;

ANIMALS; BODY WEIGHT; CHEMOKINES; DOGS; HUMANS; INFLAMMATION MEDIATORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MICE; N-ACETYLNEURAMINIC ACID; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN ENGINEERING; RECEPTORS, CELL SURFACE; RECEPTORS, VIRUS; SURVIVAL ANALYSIS;

EID: 84899646103     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404205111     Document Type: Article

References (34)

1. Salomon R, Webster RG (2009) The influenza virus enigma. Cell 136(3):402-410.
2. Gao R, et al. (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368(20):1888-1897.
3. Imai M, et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486(7403):420-428.
4. Herfst S, et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336(6088):1534-1541.
5. Russell CA, et al. (2012) The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336(6088):1541-1547.
6. Hu Y, et al. (2013) Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381(9885):2273-2279.
7. Baz M, et al. (2009) Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 361(23):2296-2297.
8. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 69:531-569.
9. Suzuki T, et al. (2001) Receptor specificities of human respiroviruses. J Virol 75(10): 4604-4613.
10. Schwegmann-Wessels C, Herrler G (2006) Sialic acids as receptor determinants for coronaviruses. Glycoconj J 23(1-2):51-58.
11. Trappetti C, et al. (2009) Sialic acid: A preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. J Infect Dis 199(10):1497-1505.
12. Shinya K, et al. (2006) Avian flu: Influenza virus receptors in the human airway. Nature 440(7083):435-436.
13. Walther T, et al. (2013) Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. PLoS Pathog 9(3):e1003223.
14. Xiong X, et al. (2013) Receptor binding by an H7N9 influenza virus from humans. Nature 499(7459):496-499.
15. Zhou J, et al. (2013) Biological features of novel avian influenza A (H7N9) virus. Nature 499(7459):500-503.
16. Mammen M, Choi SK, Whitesides GM (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 37(20):2755-2794.
17. Connaris H, Crocker PR, Taylor GL (2009) Enhancing the receptor affinity of the sialic acid-binding domain of Vibrio cholerae sialidase through multivalency. J Biol Chem 284(11):7339-7351.
18. Moustafa I, et al. (2004) Sialic acid recognition by Vibrio cholerae neuraminidase. J Biol Chem 279(39):40819-40826.
19. Xu G, Ryan C, Kiefel MJ, Wilson JC, Taylor GL (2009) Structural studies on the Pseudomonas aeruginosa sialidase-like enzyme PA2794 suggest substrate and mechanistic variations. J Mol Biol 386(3):828-840.
20. Xu G, Li X, Andrew PW, Taylor GL (2008) Structure of the catalytic domain of Streptococcus pneumoniae sialidase NanA. Acta Crystallogr Sect F Struct Biol Cryst Commun 64(Pt 9):772-775.
21. Cantor JR, et al. (2011) Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci USA 108(4):1272-1277.
22. Banerjee A, et al. (2010) Activation of brain endothelium by pneumococcal neuraminidase NanA promotes bacterial internalization. Cell Microbiol 12(11):1576-1588.
23. Ekiert DC, Wilson IA (2012) Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol 2(2):134-141.
24. Osterhaus A, Fouchier R, Rimmelzwaan G (2011) Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci 366(1579):2766-2773.
25. Boltz DA, Aldridge JR, Jr., Webster RG, Govorkova EA (2010) Drugs in development for influenza. Drugs 70(11):1349-1362.
26. Ludwig S (2011) Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol Chem 392(10): 837-847.
27. Moss RB, et al. (2012) A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 206(12):1844-1851.
28. Malakhov MP, et al. (2006) Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 50(4):1470-1479.
29. Belser JA, et al. (2007) DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196(10):1493-1499.
30. Triana-Baltzer GB, et al. (2009) Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 4(11):e7788.
31. Yamaya M, et al. (2010) Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 333(1):81-90.
32. Varki A, Gagneux P (2012) Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci 1253:16-36.
33. Varki A (2007) Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446(7139):1023-1029.
34. Morens DM, Taubenberger JK, Fauci AS (2008) Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J Infect Dis 198(7):962-970.